Shares of ImmunityBio, Inc. (NASDAQ:IBRX - Get Free Report) saw strong trading volume on Friday . 6,811,982 shares changed hands during trading, an increase of 52% from the previous session's volume of 4,470,012 shares.The stock last traded at $5.68 and had previously closed at $4.21.
Wall Street Analysts Forecast Growth
Several analysts have recently issued reports on IBRX shares. EF Hutton Acquisition Co. I raised ImmunityBio to a "strong-buy" rating in a report on Wednesday. Piper Sandler cut their price target on ImmunityBio from $6.00 to $4.75 and set a "neutral" rating on the stock in a report on Monday, August 19th.
View Our Latest Report on IBRX
ImmunityBio Trading Up 26.4 %
The company has a market cap of $3.71 billion, a price-to-earnings ratio of -5.42 and a beta of 1.02. The business has a 50-day moving average price of $3.69 and a 200 day moving average price of $5.35.
ImmunityBio (NASDAQ:IBRX - Get Free Report) last announced its quarterly earnings results on Monday, August 12th. The company reported ($0.20) earnings per share for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.03). The firm had revenue of $1.05 million for the quarter, compared to the consensus estimate of $2.53 million. On average, analysts anticipate that ImmunityBio, Inc. will post -0.86 earnings per share for the current year.
Institutional Investors Weigh In On ImmunityBio
A number of institutional investors have recently added to or reduced their stakes in IBRX. Victory Capital Management Inc. raised its position in shares of ImmunityBio by 16.0% during the 2nd quarter. Victory Capital Management Inc. now owns 19,953 shares of the company's stock valued at $126,000 after buying an additional 2,746 shares in the last quarter. Wealth Effects LLC lifted its position in ImmunityBio by 3.4% during the 3rd quarter. Wealth Effects LLC now owns 90,500 shares of the company's stock valued at $337,000 after acquiring an additional 3,000 shares during the period. Exchange Traded Concepts LLC lifted its position in ImmunityBio by 8.4% during the 3rd quarter. Exchange Traded Concepts LLC now owns 47,984 shares of the company's stock valued at $178,000 after acquiring an additional 3,722 shares during the period. Price T Rowe Associates Inc. MD grew its stake in shares of ImmunityBio by 3.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 123,879 shares of the company's stock worth $667,000 after acquiring an additional 4,533 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. grew its position in ImmunityBio by 22.0% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 25,192 shares of the company's stock valued at $99,000 after buying an additional 4,545 shares during the period. 8.58% of the stock is owned by institutional investors.
ImmunityBio Company Profile
(
Get Free Report)
ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.
Recommended Stories
Before you consider ImmunityBio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ImmunityBio wasn't on the list.
While ImmunityBio currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
